Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups Psychedelics Investing
Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval to Begin Treatments in the UK's First Medical Psychedelic Clinic Psychedelics Investing
Universal Ibogaine CEO Dr. Rami Batal: Well Funded to Develop an Innovative Addiction Treatment Model Video Interview
Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions Psychedelics Investing
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
